Metformin and Wegovy are not the same medication. They belong to different drug classes, work through entirely different biological mechanisms, and are approved for different primary purposes. Metformin is a pill that has been used for decades to manage type 2 diabetes, while Wegovy is a weekly injection of semaglutide designed specifically for chronic weight management. The two drugs are sometimes compared because both can affect body weight and blood sugar, but the similarities mostly end there.
How Each Drug Works in the Body
Metformin lowers the amount of glucose your liver produces and makes your cells more responsive to insulin. It doesn’t cause your body to make more insulin; instead, it helps the insulin you already produce work more efficiently. This is why it’s been a first-line treatment for type 2 diabetes since the 1990s.
Wegovy takes a completely different approach. Its active ingredient, semaglutide, mimics a gut hormone called GLP-1. This triggers your pancreas to release more insulin when blood sugar rises, but it also slows how quickly food leaves your stomach. That slowing effect is a big part of why people on Wegovy feel full longer and eat less. Semaglutide is the same active ingredient found in Ozempic, but Wegovy is formulated at higher doses and approved specifically for weight loss rather than diabetes management.
What Each Drug Is Approved For
Metformin is FDA-approved to treat type 2 diabetes. It is not approved for weight loss, though some people do lose a modest amount of weight while taking it. Doctors sometimes prescribe it off-label for conditions like polycystic ovary syndrome (PCOS) or prediabetes, but weight management isn’t its intended role.
Wegovy is FDA-approved for chronic weight management in adults with obesity (a BMI of 30 or higher) or adults who are overweight (BMI of 27 or higher) with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. It’s meant to be used alongside a reduced-calorie diet and increased physical activity.
Weight Loss: A Significant Gap
This is where the two drugs diverge most dramatically. Metformin produces modest weight loss in some people, typically in the range of 2 to 5 percent of body weight. Many people on metformin don’t lose meaningful weight at all. It was never designed as a weight loss drug, and any effect on the scale is more of a side benefit than a primary outcome.
Wegovy, by contrast, was developed specifically to reduce body weight. In clinical trials, people taking the full dose of semaglutide lost an average of about 15 percent of their body weight over 68 weeks. For someone weighing 250 pounds, that’s roughly 37 pounds. This level of weight loss puts Wegovy in a different category entirely from metformin.
How You Take Them
Metformin comes as an oral tablet or liquid that you take once or twice daily with meals. It’s one of the most widely prescribed medications in the world, and generic versions have been available for years, making it very affordable. Most people pay only a few dollars a month.
Wegovy is a subcutaneous injection, meaning you inject it just under the skin using a prefilled pen, once per week. The dose starts low and gradually increases over several months to reduce side effects. Because Wegovy is a newer brand-name biologic, it costs significantly more, often over $1,000 per month without insurance. Coverage varies widely between insurance plans.
Side Effects
Both medications can cause gastrointestinal side effects, which is one reason people sometimes confuse them. Metformin commonly causes diarrhea, nausea, and stomach discomfort, especially when you first start taking it or when the dose increases. These effects usually improve over a few weeks, and extended-release versions tend to be easier on the stomach.
Wegovy’s most common side effects are also gastrointestinal: nausea, vomiting, diarrhea, and constipation. Nausea is particularly common during the dose-escalation phase and tends to lessen as your body adjusts. The gradual increase in dosing is specifically designed to minimize these effects.
The safety warnings differ in important ways. Metformin carries a warning about a rare but serious condition called lactic acidosis, particularly in people with kidney problems. Wegovy’s prescribing information includes a warning about the risk of a rare type of thyroid tumor, based on findings in animal studies. The FDA has also noted that prescribing information for GLP-1 medications like Wegovy includes information about the risk of suicidal thoughts, and patients are advised to report any unusual changes in mood or behavior.
Can You Take Both Together?
Yes. There are no known drug interactions between metformin and Wegovy, and many people with type 2 diabetes take both. Metformin handles the underlying insulin resistance while Wegovy addresses weight and provides additional blood sugar control through a separate pathway. For people managing both diabetes and obesity, using the two together can target multiple aspects of metabolic health at once.
Which One Is Right for You
If your primary concern is managing type 2 diabetes and you don’t have significant weight to lose, metformin is a well-established, inexpensive option with decades of safety data. If weight loss is the main goal and you meet the BMI criteria, Wegovy offers substantially greater results but at a much higher cost and with the commitment of weekly injections. Some people benefit from both. The choice depends on your specific health picture, what your insurance covers, and what you’re trying to accomplish.